KIT and Miyoshi myopathy: Despite the time lapse since the study conception and the advancements in the analytical technologies that have become available, there have been no breakthrough advances in terms of targeted therapy for AM and MM, no dedicated randomized Phase III trials, and KIT inhibitors remain unlicensed in most countries.